Should You Buy Varex Imaging Corporation Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Varex Imaging Corporation (VREX) carries a solid Quality of Company rating of 7.3/10. Trading at $18.47, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 3 of 7 CirclFi valuation models project upside for Varex Imaging Corporation (VREX) at $18.47 — the model consensus leans bearish, with a Quality Score of 7.3/10 and Value-Trap risk of 27/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Varex Imaging Corporation (VREX) in 2026?
What Is the Bull Case vs the Bear Case for Varex Imaging Corporation (VREX)?
| Bull case — $31.81 target (+72.2%) | Bear case — $4.39 target (-76.2%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Varex Imaging Corporation's score of 7.3/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $4.39 (-76.2%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $31.81 (+72.2%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +148.4% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for Varex Imaging Corporation's revenue and margin trajectory in the Medical Devices space. | Industry headwind: drug pricing legislation represents a meaningful risk for Varex Imaging Corporation and its Medical Devices peers. |
How Does VREX Compare to Its Medical Devices Peers?
Valuation data pages: SNWV · SRTS · DCTH · AORT · SIBN · SGHT · PETV · NUWE · ICCM · IRMD · PODD
Which Other Stocks Score Like VREX on Quality?
Closest companies to VREX’s Quality of Company score of 7.3/10, across all industries.
- CVI — CVR Energy, Inc. (QOC 7.3) · analysis
- HCC — Warrior Met Coal, Inc. (QOC 7.3) · analysis
- GTLB — GitLab Inc. (QOC 7.3) · analysis
- VG — Venture Global, Inc. (QOC 7.3) · analysis
- CSTL — Castle Biosciences, Inc. (QOC 7.3) · analysis
- MRTN — Marten Transport, Ltd. (QOC 7.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does VREX Appear In?
So Is Varex Imaging Corporation (VREX) Worth Buying in 2026?
Caution dominates our read on Varex Imaging Corporation at $18.47. 4 of 7 models see limited upside or outright downside, with the median fair value at $12.61 (-31.8%). Quality at 7.3/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Varex Imaging Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About VREX Stock?
Should I buy VREX stock right now?
Based on CirclFi's multi-model analysis, 3 of 7 models see upside for VREX at $18.47. The models are divided, which means the investment case depends heavily on your assumptions about Varex Imaging Corporation's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Varex Imaging Corporation?
Key risks include: limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (624% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does VREX compare to its competitors?
Among Medical Devices peers, VREX holds a Quality Score of 7.3/10. Comparable companies include SNWV (QOC 7.4), SRTS (QOC 7.3), DCTH (QOC 7.4). The relative ranking helps investors identify whether VREX offers better fundamental quality than alternatives in the same sector.
Is VREX a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. VREX's Quality Score of 7.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy VREX at?
CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $4.39 to $31.81. At $18.47, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for VREX.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad